Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary

Zenas BioPharma

13/08/2026 13:06

Zenas BioPharma, Inc. ZBIO.OQ reported a quarterly adjusted loss of $1.29​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-1.25.  The mean expectation of six analysts for the quarter was for a loss of $1.12 per share. Wall Street expected results to range from $-1.46 to -12 cents per share.
Revenue was $1.00 million​; analysts expected $18.75 million. 
Zenas BioPharma, Inc.'s reported EPS for the quarter was a loss of $1.77​.
The company reported a quarterly loss of $111.46 million.
Zenas BioPharma, Inc. shares had risen by 23.3% this quarter and lost 13.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Zenas BioPharma, Inc. is $44.50, about 29.7% above its last closing price of $31.29
This summary was machine generated from LSEG data August 13 at 12:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.12
-1.29
Missed
Mar. 31 2026 
-1.59
-1.46
Beat
Dec. 31 2025 
-1.03
-4.54
Missed
Sep. 30 2025 
-1.05
-1.22
Missed